Evercore ISI lowered the firm’s price target on Caris Life Sciences (CAI) to $38 from $40 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have “set the stage for a 2026 Tools play,” the analyst tells investors. In MedTech, the firm’s survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes “have bears watching,” the analyst added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences price target raised to $30 from $28 at Canaccord
- BLSH, SLMT, CAI: Cathie Wood Loads Up on Crypto and Healthcare Stocks, Trims a Consumer Tech Name
- Caris Life Sciences partners with Roche’s Genentechh for cancer targets
- Caris Life Sciences price target lowered to $35 from $39 at BofA
- Caris Life Sciences initiated with a Hold at Canaccord